Prosecution Insights
Last updated: April 19, 2026

Examiner: MCINTOSH III, TRAVISS C

Tech Center 1600 • Art Units: 1623 1673 1693

This examiner grants 73% of resolved cases

Performance Statistics

73.2%
Allow Rate
+13.2% vs TC avg
1340
Total Applications
+13.9%
Interview Lift
958
Avg Prosecution Days
Based on 1312 resolved cases, 2023–2026

Rejection Statute Breakdown

3.5%
§101 Eligibility
24.3%
§102 Novelty
14.8%
§103 Obviousness
31.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19346873 MARIBAVIR ISOMERS, COMPOSITIONS, METHODS OF MAKING AND METHODS OF USING Non-Final OA Takeda Pharmaceutical Company Limited
17799393 METHODS FOR RAPID SYNTHESIS OF PYRANOANTHOCYANINS Non-Final OA Ohio State Innovation Foundation
18744247 KAEMPFEROL ANALOG-CONTAINING COMPOSITION Non-Final OA OTSUKA PHARMACEUTICAL CO., LTD.
17550271 LONG STOKES SHIFT CHROMENOQUINOLINE DYES AND USES IN SEQUENCING APPLICATIONS Final Rejection Illumina Cambridge Limited
18560242 COMBINATION THERAPIES Non-Final OA Janssen Pharmaceutica NV
18258731 PENETRATING CRYOPROTECTION AGENTS AND METHODS OF MAKING AND USING SAME Non-Final OA The Research Foundation for The State University of New York
18321563 Pet Food Compositions Non-Final OA Hill's Pet Nutrition, Inc.
18495216 NONWOVEN GLUCAN WEBS Non-Final OA NUTRITION & BIOSCIENCES USA 4, INC.
18739149 NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS Final Rejection Atea Pharmaceuticals, Inc.
18252394 MODIFIED SOPHOROLIPID FOR IMPROVED BIOAVAILABILITY OF AMINO ACIDS AND METHOD OF USE Final Rejection LOCUS SOLUTIONS IPCO, LLC
18571137 PHARMACEUTICAL COMPOSITION FOR INCREASING MITOCHONDRIAL ACTIVITY AND/OR IMPROVING ADIPONECTIN PRODUCTION Non-Final OA LOGICK ENERGETICS B.V.
18386643 PURIFICATION METHOD FOR SUCRALOSE-6-ETHYL ESTER Non-Final OA ANHUI JINHE INDUSTRIAL CO., LTD.
18483622 BIOSYNTHETIC PRODUCTION OF STEVIOL GLYCOSIDES Non-Final OA Conagen Inc.
18477929 HETEROCYCLIC INHIBITORS OF CD73 FOR TREATMENT OF DISEASE Non-Final OA Teon Therapeutics, Inc.
18477946 HETEROCYCLIC INHIBITORS OF CD73 FOR TREATMENT OF DISEASE Non-Final OA Teon Therapeutics, Inc.
17844407 BIVALENT COMPOUNDS, CONJUGATES AND USES THEREOF Final Rejection RISEN (SUZHOU) PHARMA TECH CO., LTD.
18281211 HEMOSTATIC MATERIAL Non-Final OA ARTISAN LAB CO., LTD.
18280527 3'3' CYCLIC DINUCLEOTIDES CONTAINING ISONUCLEOTIDIC UNITS Non-Final OA INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR, V. V. I.
18279150 GLUCOCEREBROSIDE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF Non-Final OA DONGGUAN HEC CORDYCEPS R&D CO., LTD.
18022855 PROCESS FOR THE DIRECT CONVERSION OF CELLULOSE TO GLYCOLS USING NON-NOBLE METAL LOADED ZEOLITE CATALYSTS Non-Final OA COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
18323272 PREPARATION METHOD FOR AND APPLICATION OF CLASS OF STELLATE BIFUNCTIONAL COMPOUNDS TARGETING SPIKE PROTEIN AGAINST RESPIRATORY TRACT INFECTION VIRUS AND SALT THEREOF Non-Final OA SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD.
17429113 COMPOSITION FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION Non-Final OA SAN-EI GEN F.F.I., INC.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month